Please assess the completion status of the following clinical trial:

Trial Title: Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* idiopathic PD with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry (in accordance with clinical diagnostic criteria of the UK PD Society Brain Bank);~* the presence of minor VH for at least 4 weeks, defined by a score of 1 or 2 on the hallucinations item of the Unified Parkinson's Disease rating Scale (UPDRS)1-MDS;~* age 40 years and over.~Exclusion Criteria:~* Parkinson's Disease Psychosis, defined as the need for antipsychotic drug treatment in the opinion of the treating neurologist;~* Parkinson's Disease Dementia, defined by a score \< 24 on the Mini Mental State Examination (MMSE);~* current delirium (caused by infection or metabolic disturbance);~* current treatment with amantadine (Symmetrel) or anti-cholinergics, such as trihexyfenidyl (Artane) or biperideen (Akineton);~* current or recent (\<6 months) treatment with Cholinesterase inhibitor, such as rivastigmine (Exelon) or galantamine (Reminyl);~* recent (\<1 month) change in dopaminergic therapy;~* history of psychosis or severe ophtalmologic disease (e.g. Charles Bonnet syndrome);~* permanent stay in a nursing home;~* no informed consent.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo capsule for oral use 6,0 mg BID during 24 months of follow-up
- Rivastigmine (Type: EXPERIMENTAL): rivastigmine capsule for oral use 6,0 mg BID during 24 months of follow-up

Based on this trial design, predict the completion outcome and termination type (if applicable).